

=> fil cap  
FILE 'CAPLUS' ENTERED AT 14:30:46 ON 17 DEC 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 17 Dec 2008 VOL 149 ISS 25  
FILE LAST UPDATED: 16 Dec 2008 (20081216/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> d que 116  
L1 STR



VAR G1=H/OH  
VAR G2=CH2/O/NH/23  
VAR G3=PH/25/28/31/34/37  
VAR G4=X/CN/45/46/48/50  
VAR G5=C/N  
NODE ATTRIBUTES:


CONNECT IS E3 RC AT 1  
 CONNECT IS E2 RC AT 2  
 CONNECT IS E2 RC AT 3  
 CONNECT IS E2 RC AT 5  
 CONNECT IS E2 RC AT 6  
 CONNECT IS E2 RC AT 7  
 CONNECT IS E2 RC AT 9  
 CONNECT IS E2 RC AT 10  
 CONNECT IS E2 RC AT 12  
 CONNECT IS E2 RC AT 13  
 CONNECT IS E1 RC AT 24  
 CONNECT IS E2 RC AT 25  
 CONNECT IS E3 RC AT 28  
 CONNECT IS E4 RC AT 31  
 CONNECT IS E5 RC AT 34  
 CONNECT IS E6 RC AT 37  
 CONNECT IS E1 RC AT 45  
 CONNECT IS E1 RC AT 49  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS LOC SAT AT 24  
 GGCAT IS MCY UNS AT 25  
 GGCAT IS MCY UNS AT 28  
 GGCAT IS MCY UNS AT 31  
 GGCAT IS MCY UNS AT 34  
 GGCAT IS MCY UNS AT 37  
 GGCAT IS LOC SAT AT 45  
 GGCAT IS LOC SAT AT 46  
 GGCAT IS LOC SAT AT 49  
 GGCAT IS LOC SAT AT 51  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E6 C AT 25  
 ECOUNT IS E6 C AT 28  
 ECOUNT IS E6 C AT 31  
 ECOUNT IS E6 C AT 34  
 ECOUNT IS E6 C AT 37

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 52

## STEREO ATTRIBUTES: NONE

L3 149 SEA FILE=REGISTRY SSS FUL L1  
 L8 STR



REP G1=(0-2) A

VAR G2=H/11/12

## NODE ATTRIBUTES:

CONNECT IS E1 RC AT 11  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS SAT AT 11  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS UNLIMITED AT 2 3 4

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

L10 138 SEA FILE=REGISTRY SUB=L3 SSS FUL L8  
L16 4 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L10

=> fil wpix  
FILE 'WPIX' ENTERED AT 14:30:53 ON 17 DEC 2008  
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE LAST UPDATED: 12 DEC 2008 <20081212/UP>

MOST RECENT UPDATE: 200880 <200880/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> Now containing more than 1.2 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to end of September 2008. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC, and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC, 20071130/UPIC, 20080401/UPIC, 20080701/UPIC and 20081001/UPIC.  
ECLA reclassifications to mid August and US national classification mid September 2008 have also been loaded. Update dates 20080401, 20080701 and 20081001/UPEC and /UPNC have been assigned to these. <<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:

[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf)

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE


<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:

[http://www.stn-international.com/DWPAnaVist2\\_0608.html](http://www.stn-international.com/DWPAnaVist2_0608.html)

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

=> d que 113  
L1 STR



VAR G1=H/OH  
 VAR G2=CH2/O/NH/23  
 VAR G3=PH/25/28/31/34/37  
 VAR G4=X/CN/45/46/48/50  
 VAR G5=C/N

NODE ATTRIBUTES:


CONNECT IS E3 RC AT 1  
 CONNECT IS E2 RC AT 2  
 CONNECT IS E2 RC AT 3  
 CONNECT IS E2 RC AT 5  
 CONNECT IS E2 RC AT 6  
 CONNECT IS E2 RC AT 7  
 CONNECT IS E2 RC AT 9  
 CONNECT IS E2 RC AT 10  
 CONNECT IS E2 RC AT 12  
 CONNECT IS E2 RC AT 13  
 CONNECT IS E1 RC AT 24  
 CONNECT IS E2 RC AT 25  
 CONNECT IS E3 RC AT 28  
 CONNECT IS E4 RC AT 31  
 CONNECT IS E5 RC AT 34  
 CONNECT IS E6 RC AT 37  
 CONNECT IS E1 RC AT 45  
 CONNECT IS E1 RC AT 49  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS LOC SAT AT 24  
 GGCAT IS MCY UNS AT 25  
 GGCAT IS MCY UNS AT 28  
 GGCAT IS MCY UNS AT 31  
 GGCAT IS MCY UNS AT 34  
 GGCAT IS MCY UNS AT 37  
 GGCAT IS LOC SAT AT 45  
 GGCAT IS LOC SAT AT 46  
 GGCAT IS LOC SAT AT 49  
 GGCAT IS LOC SAT AT 51  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E6 C AT 25  
 ECOUNT IS E6 C AT 28

ECOUNT IS E6 C AT 31  
 ECOUNT IS E6 C AT 34  
 ECOUNT IS E6 C AT 37

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE  
 L8 STR



REP G1=(0-2) A  
 VAR G2=H/11/12  
 NODE ATTRIBUTES:  
 CONNECT IS E1 RC AT 11  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS SAT AT 11  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS UNLIMITED AT 2 3 4

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE  
 L12 3 SEA FILE=WPIX SSS FUL L1 AND L8  
 L13 2 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L12/DCR

=> dup rem l16 l13  
 FILE 'CAPLUS' ENTERED AT 14:31:00 ON 17 DEC 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 14:31:00 ON 17 DEC 2008  
 COPYRIGHT (C) 2008 THOMSON REUTERS  
 PROCESSING COMPLETED FOR L16  
 PROCESSING COMPLETED FOR L13  
 L17 4 DUP REM L16 L13 (2 DUPLICATES REMOVED)  
 ANSWERS '1-4' FROM FILE CAPLUS

=> d l17 ibib abs hitstr tot

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1  
 ACCESSION NUMBER: 2005:1126684 CAPLUS Full-text  
 DOCUMENT NUMBER: 143:405806  
 TITLE: Preparation of piperidine derivatives for the  
 treatment of chemokine mediated diseases  
 INVENTOR(S): Mochel, Tobias; Perry, Matthew; Springthorpe, Brian  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:


English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097775	A1	20051020	WO 2005-SE495	20050405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1735298	A1	20061227	EP 2005-722310	20050405
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1964964	A	20070516	CN 2005-80018458	20050405
JP 2007532535	T	20071115	JP 2007-507274	20050405
IN 2006DN05542	A	20070803	IN 2006-DN5542	20060922
US 20080262037	A1	20081023	US 2007-599700	20070216
PRIORITY APPLN. INFO.:			SE 2004-925	A 20040406
			WO 2005-SE495	W 20050405

OTHER SOURCE(S): CASREACT 143:405806; MARPAT 143:405806  
GI



I



II

AB Title compds. I [R1 = (un)substituted phenyl; W = O or bond; Q = H or OH; one of A, B, D, E and G = C-X-Y-CO2R5, another is CH or N and the others are CR2, CR3 and CR4; X = CH2, O, NH, or N-alkyl; Y = (un)substituted linking alkyl; R5 = H, alkyl, benzyl; R2-4 independently = H, halo, CN, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed for treatment of diseases mediated by chemokine (such as CCR3) or histamine receptors. Thus, e.g., II was prepared via hydrolysis of corresponding Me ester (preparation given). I were evaluated for binding to histamine H1 receptors, e.g., II


demonstrated a pKi value of 8.3. Assays for chemokine receptor activity were also described.

IT 867218-97-1P 867219-01-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of piperidine derivs. for the treatment of chemokine mediated diseases)


RN 867218-97-1 CAPLUS

CN Benzeneacetic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867219-01-0 CAPLUS

CN Acetic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 867218-98-2P 867218-99-3P 867219-00-9P  
867219-02-1P 867219-03-2P 867219-04-3P  
867219-05-4P 867219-06-5P 867219-07-6P  
867219-08-7P 867219-09-8P 867219-10-1P  
867219-11-2P 867219-12-3P 867219-13-4P  
867219-14-5P 867219-15-6P 867219-16-7P  
867219-17-8P 867219-18-9P 867219-19-0P  
867219-20-3P 867219-22-5P 867219-23-6P  
867219-24-7P 867219-25-8P 867219-26-9P  
867219-27-0P 867219-28-1P 867219-29-2P  
867219-30-5P 867219-31-6P 867219-32-7P  
867219-33-8P 867219-34-9P 867219-35-0P  
867219-36-1P 867219-37-2P 867219-38-3P  
867219-40-7P 867219-41-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine derivs. for the treatment of chemokine mediated diseases)


RN 867218-98-2 CAPLUS

CN Benzeneacetic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl-, methyl ester (CA INDEX NAME)




RN 867218-99-3 CAPLUS

CN Benzeneacetic acid, 4-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl-, methyl ester (CA INDEX NAME)




RN 867219-00-9 CAPLUS

CN Benzeneacetic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methoxy-, methyl ester (CA INDEX NAME)




RN 867219-02-1 CAPLUS

CN Acetic acid, 2-[3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 867219-03-2 CAPLUS

CN Acetic acid, 2-[4-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 867219-04-3 CAPLUS


CN Propanoic acid, 2-[2-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 867219-05-4 CAPLUS

CN Propanoic acid, 2-[2-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]phenoxy]-, methyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 867219-06-5 CAPLUS

CN Propanoic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, methyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 867219-07-6 CAPLUS

CN Propanoic acid, 2-[3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, methyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 867219-08-7 CAPLUS


CN Propanoic acid, 2-[3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, methyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 867219-09-8 CAPLUS

CN Benzene propanoic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 867219-10-1 CAPLUS

CN Benzeneacetic acid, 4-[4-[(4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 867219-11-2 CAPLUS

CN Benzeneacetic acid, 4-[4-[(4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 867219-12-3 CAPLUS

CN Benzeneacetic acid, 3-[4-[(4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867219-13-4 CAPLUS


CN Benzeneacetic acid, 4-[4-[(4-(3-chloro-4-cyano-2-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867219-14-5 CAPLUS


CN Propanoic acid, 2-[3-[(4-(3-chloro-4-cyano-2-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]phenoxy]-, methyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 867219-15-6 CAPLUS

CN Benzeneacetic acid, 3-[4-[(4-(3,4-dichloro-2-ethylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 867219-16-7 CAPLUS

CN Benzeneacetic acid, 3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 867219-17-8 CAPLUS

CN Benzeneacetic acid, 2-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl- (CA INDEX NAME)




RN 867219-18-9 CAPLUS

CN Benzeneacetic acid, 4-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl- (CA INDEX NAME)




RN 867219-19-0 CAPLUS

CN Benzeneacetic acid, 3-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methoxy- (CA INDEX NAME)




RN 867219-20-3 CAPLUS

CN Acetic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]- (CA INDEX NAME)




RN 867219-22-5 CAPLUS

CN Acetic acid, 2-[3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]- (CA INDEX NAME)




RN 867219-23-6 CAPLUS

CN Acetic acid, 2-[4-[[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]- (CA INDEX NAME)



RN 867219-24-7 CAPLUS


CN Propanoic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-2-methyl- (CA INDEX NAME)



RN 867219-25-8 CAPLUS

CN Propanoic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 867219-26-9 CAPLUS

CN Propanoic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 867219-27-0 CAPLUS

CN Propanoic acid, 2-[3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 867219-28-1 CAPLUS


CN Propanoic acid, 2-[3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]phenoxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 867219-29-2 CAPLUS

CN Benzene propanoic acid, 2-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 867219-30-5 CAPLUS

CN Benzeneacetic acid, 4-[(4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl)acetyl]- (CA INDEX NAME)




RN 867219-31-6 CAPLUS

CN Benzeneacetic acid, 4-[4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 867219-32-7 CAPLUS

CN Benzeneacetic acid, 3-[4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 867219-33-8 CAPLUS


CN Benzeneacetic acid, 4-[4-[[4-(3-chloro-4-cyano-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 867219-34-9 CAPLUS

CN Propanoic acid, 2-[3-[4-[[4-(3-chloro-4-cyano-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 867219-35-0 CAPLUS  
 CN Benzeneacetic acid, 3-[4-[[4-(3,4-dichloro-2-ethylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl- (CA INDEX NAME)




RN 867219-36-1 CAPLUS  
 CN Acetic acid, 2-[4-chloro-2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 867219-37-2 CAPLUS  
 CN Acetic acid, 2-[2-chloro-6-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]- (CA INDEX NAME)



RN 867219-38-3 CAPLUS


CN Acetic acid, 2-[2-[4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methylphenoxy]- (CA INDEX NAME)



RN 867219-40-7 CAPLUS


CN Propanoic acid, 2-[3-[4-[[4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-41-8 CAPLUS

CN Benzeneacetic acid, 3-[4-[[4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)





REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT.

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2  
ACCESSION NUMBER: 2004:996129 CAPLUS Full-text  
DOCUMENT NUMBER: 141:424114  
TITLE: Preparation of 1-aryl (aryloxy)- or  
(aryl methyl)piperidinemethylpiperidines as histamine  
H1 receptor binding agents for treatment of  
chemokine-mediated diseases  
INVENTOR(S): Luckhurst, Christopher; Mochel, Tobias; Perry,  
Matthew; Springthorpe, Brian; Stein, Linda  
PATENT ASSIGNEE(S): AstraZeneca Ab, Swed.  
SOURCE: PCT Int. Appl., 72 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099144	A1	20041118	WO 2004-SE693	20040506
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1625114	A1	20060215	EP 2004-731523	20040506
EP 1625114	B1	20080827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2006525996	T	20061116	JP 2006-508044	20040506
AT 406353	T	20080915	AT 2004-731523	20040506
US 20060264463	A1	20061123	US 2005-556107	20051108
PRIORITY APPLN. INFO.:			SE 2003-1368	A 20030509

OTHER SOURCE(S): MARPAT 141:424114  
GI



AB Compds. I [A, B, D, E, G = R5O2CC, R2C, HC, N, HO; W = alkylimino, NH, O, H2C; X = (CH2)m; Y = (CH2)n; R1 = (un)substituted phenyl; R2 = H, halo, NC, alkyl, haloalkyl, alkoxy, haloalkoxy; R5 = H, alkyl, PhCH2; m, n = 0, 1] such as II are prepared as histamine H1 receptor binding agents for the treatment of chemokine-mediated diseases. E.g., reductive amination of 4-(3,4-dichlorophenoxy)piperidine with 1-Boc-4-formylpiperidine and sodium triacetoxyborohydride, cleavage of the Boc group with trifluoroacetic acid, and nucleophilic aromatic substitution of Me 2-fluorobenzoate with the aryloxy piperidinemethylpiperidine yields II. The pKi values for displacement of a ligand from human histamine H1 receptors are determined for some of the invention compds. E.g., II displaces a ligand from human histamine H1 receptors with a pKi value of 8.6. Methods for preparing the title compds. are claimed.


IT 796592-57-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(invention compound; preparation of 1-aryl (aryloxy)- or (arylmethyl)piperidinemethylpiperidines as histamine H1 receptor binding agents for treatment of chemokine-mediated diseases)

RN 796592-57-9 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



IT 796592-63-7P 796592-67-1P 796592-73-9P  
 796592-79-5P 796592-84-2P 796592-90-0P  
 796592-95-5P 796593-01-6P 796593-07-2P


796593-11-8P 796593-17-4P 796593-23-2P  
 796593-27-6P 796593-67-4P 796593-77-6P  
 796593-83-4P 796593-89-0P 796593-96-9P  
 796594-00-8P 796594-07-5P 796594-13-3P  
 796594-18-8P 796594-25-7P 796594-30-4P  
 796594-38-2P 796594-43-9P 796594-50-8P  
 796594-56-4P 796594-63-3P 796594-76-8P  
 796594-82-6P 796594-86-0P 796594-94-0P  
 796595-00-1P 796595-08-9P 796595-14-7P  
 796595-21-6P 796595-28-3P 796595-35-2P  
 796595-42-1P 796595-48-7P 796595-55-6P  
 796595-60-3P 796595-68-1P 796595-73-8P  
 796595-80-7P 796595-86-3P 796595-94-3P  
 796596-01-5P 796596-08-2P 796596-15-1P  
 796596-22-0P 796596-29-7P 796596-36-6P  
 796596-44-6P 796596-52-6P 796596-59-3P  
 796596-67-3P 796596-73-1P 796596-80-0P  
 796596-86-6P 796596-91-3P 796596-99-1P  
 796597-04-1P 796597-13-2P 796597-18-7P  
 796597-25-6P 796597-31-4P 796597-38-1P  
 796597-46-1P 796597-53-0P 796597-60-9P  
 796597-68-7P 796597-75-6P 796597-82-5P  
 796597-89-2P 796598-31-7P 796598-42-0P  
 796598-55-5P 796598-62-4P 796598-69-1P  
 796598-76-0P 796598-83-9P 796598-90-8P  
 796598-97-5P 796599-05-8P 796599-12-7P  
 796599-19-4P 796599-26-3P 796599-33-2P  
 796599-40-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compound; preparation of 1-aryl (aryloxy)- or (arylmethyl)piperidinemethylpiperidines as histamine H1 receptor binding agents for treatment of chemokine-mediated diseases)


RN 796592-63-7 CAPLUS

CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl-, methyl ester (CA INDEX NAME)




RN 796592-67-1 CAPLUS

CN Benzoic acid, 2-[4-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl-, methyl ester (CA INDEX NAME)




RN 796592-73-9 CAPLUS

CN Benzoic acid, 4-chloro-2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 796592-79-5 CAPLUS

CN Benzoic acid, 2-[4-[[4-(2-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 796592-84-2 CAPLUS

CN Benzoic acid, 4-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)




RN 796592-90-0 CAPLUS

CN Benzoic acid, 4-chloro-2-[4-[(4-chlorophenoxy)methyl]piperidinyl]-1-piperidinyl-, methyl ester (CA INDEX NAME)




RN 796592-95-5 CAPLUS

CN Benzoic acid, 3-chloro-4-[(4-chlorophenoxy)methyl]piperidinyl-1-piperidinyl-, methyl ester (CA INDEX NAME)




RN 796593-01-6 CAPLUS

CN Benzoic acid, 2-chloro-4-[(4-chlorophenoxy)methyl]piperidinyl-1-piperidinyl-, methyl ester (CA INDEX NAME)




RN 796593-07-2 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-4-methyl-, methyl ester (CA INDEX NAME)




RN 796593-11-8 CAPLUS

CN Benzoic acid, 2-[4-[(4-(4-chlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 796593-17-4 CAPLUS

CN Benzoic acid, 3-chloro-2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 796593-23-2 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-4-hydroxy-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 796593-27-6 CAPLUS

CN Benzoic acid, 2-[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]-4-methyl-, methyl ester (CA INDEX NAME)




RN 796593-67-4 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3-chloro-4-cyano-2-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 796593-77-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 796593-83-4 CAPLUS

CN Benzoic acid, 3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)




RN 796593-89-0 CAPLUS

CN Benzoic acid, 3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)




RN 796593-96-9 CAPLUS

CN Benzoic acid, 3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-4-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 796594-00-8 CAPLUS

CN Benzoic acid, 4-chloro-3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 796594-07-5 CAPLUS

CN Benzoic acid, 3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-4-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 796594-13-3 CAPLUS

CN Benzoic acid, 3-[4-[(4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 796594-18-8 CAPLUS

CN Benzoic acid, 2-chloro-5-[4-[(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 796594-25-7 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[4-[(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 796594-30-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 796594-38-2 CAPLUS

CN Benzoic acid, 3-[4-[(4-[(3,4-dichlorophenyl)methyl]-1-piperidinyl)methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)




RN 796594-43-9 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796594-50-8 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796594-56-4 CAPLUS

CN Benzoic acid, 2-[4-[(4-(4-fluorophenyl)methyl)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796594-63-3 CAPLUS

CN Benzoic acid, 4-chloro-2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796594-76-8 CAPLUS

CN Benzoic acid, 4-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796594-82-6 CAPLUS


CN Benzoic acid, 4-chloro-2-[4-[(4-(2-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796594-86-0 CAPLUS  
 CN Benzoic acid, 3-chloro-4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl- (CA INDEX NAME)




RN 796594-94-0 CAPLUS  
 CN Benzoic acid, 2-chloro-4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl- (CA INDEX NAME)



RN 796595-00-1 CAPLUS  
 CN Benzoic acid, 2-[[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methyl- (CA INDEX NAME)




RN 796595-08-9 CAPLUS  
 CN Benzoic acid, 2-[[4-[[4-(4-chlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methyl- (CA INDEX NAME)




RN 796595-14-7 CAPLUS

CN Benzoic acid, 2-[4-[(4-chlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl- (CA INDEX NAME)




RN 796595-21-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 796595-28-3 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-5-nitro- (CA INDEX NAME)




RN 796595-35-2 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-6-methyl- (CA INDEX NAME)




RN 796595-42-1 CAPLUS

CN Benzoic acid, 3-chloro-2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl- (CA INDEX NAME)




RN 796595-48-7 CAPLUS

CN Benzoic acid, 2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl- (CA INDEX NAME)




RN 796595-55-6 CAPLUS

CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 796595-60-3 CAPLUS

CN Benzoic acid, 5-chloro-2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796595-68-1 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 796595-73-8 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-3-fluoro- (CA INDEX NAME)




RN 796595-80-7 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-5-fluoro- (CA INDEX NAME)




RN 796595-86-3 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)




RN 796595-94-3 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)




RN 796596-01-5 CAPLUS

CN Benzoic acid, 2-[4-[(4-(4-chloro-2-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-3-fluoro- (CA INDEX NAME)




RN 796596-08-2 CAPLUS

CN Benzoic acid, 2-[4-[(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl-5-(trifluoromethyl)- (CA INDEX NAME)




RN 796596-15-1 CAPLUS

CN Benzoic acid, 2-[4-[(4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-nitro- (CA INDEX NAME)



RN 796596-22-0 CAPLUS


CN Benzoic acid, 2-[4-[(4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)



RN 796596-29-7 CAPLUS


CN Benzoic acid, 2-[4-[(4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-

piperidinyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 796596-36-6 CAPLUS

CN Benzoic acid, 4-chloro-2-[4-[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796596-44-6 CAPLUS

CN Benzoic acid, 2-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 796596-52-6 CAPLUS


CN Benzoic acid, 2-[4-[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-fluoro- (CA INDEX NAME)




RN 796596-59-3 CAPLUS  
 CN Benzoic acid, 3-chloro-2-[4-[(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796596-67-3 CAPLUS  
 CN Benzoic acid, 5-chloro-2-[4-[(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796596-73-1 CAPLUS  
 CN Benzoic acid, 2-[4-[(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 796596-80-0 CAPLUS

CN Benzoic acid, 2-[4-[(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-3-fluoro- (CA INDEX NAME)




RN 796596-86-6 CAPLUS

CN Benzoic acid, 2-[4-[(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-fluoro- (CA INDEX NAME)




RN 796596-91-3 CAPLUS

CN Benzoic acid, 2-[4-[(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 796596-99-1 CAPLUS

CN Benzoic acid, 2-[4-[(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)




RN 796597-04-1 CAPLUS

CN Benzoic acid, 5-chloro-2-[(4-[(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796597-13-2 CAPLUS

CN Benzoic acid, 2-[(4-[(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)




RN 796597-18-7 CAPLUS

CN Benzoic acid, 4-chloro-2-[(4-[(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796597-25-6 CAPLUS

CN Benzoic acid, 3-chloro-2-[(4-[(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl)-1-piperidinyl]- (CA INDEX NAME)




RN 796597-31-4 CAPLUS

CN Benzoic acid, 2-[4-[(4-(4-chloro-3-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)




RN 796597-38-1 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-6-fluoro- (CA INDEX NAME)




RN 796597-46-1 CAPLUS

CN Benzoic acid, 2-[4-[(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-4-methoxy- (CA INDEX NAME)




RN 796597-53-0 CAPLUS

CN Benzoic acid, 2-[4-[(4-[(3,4-dichlorophenyl)methyl]-1-piperidinyl)methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)




RN 796597-60-9 CAPLUS

CN Benzoic acid, 2-[4-[(4-chlorophenyl)methyl]-1-piperidinyl)methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)




RN 796597-68-7 CAPLUS

CN Benzoic acid, 2-[4-[(4-chlorophenyl)methyl]-1-piperidinyl)methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)




RN 796597-75-6 CAPLUS

CN Benzoic acid, 2-[4-[(4-[(3,4-dichlorophenyl)methyl]-1-piperidinyl)methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)




RN 796597-82-5 CAPLUS

CN Benzoic acid, 2-[4-[(4-[(4-fluorophenyl)methyl]-1-piperidinyl)methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)



RN 796597-89-2 CAPLUS


CN Benzoic acid, 2-[4-[(4-[(4-fluorophenyl)methyl]-1-piperidinyl)methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)



RN 796598-31-7 CAPLUS


CN Benzoic acid, 2-[4-[(4-[(3-chloro-4-cyano-2-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)

piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796598-42-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796598-55-5 CAPLUS

CN Benzoic acid, 3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796598-62-4 CAPLUS

CN Benzoic acid, 3-[4-[(4-(4-chlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796598-69-1 CAPLUS

CN Benzoic acid, 3-[4-[(4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796598-76-0 CAPLUS

CN Benzoic acid, 3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-4-methyl- (CA INDEX NAME)




RN 796598-83-9 CAPLUS

CN Benzoic acid, 3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-2-methyl- (CA INDEX NAME)




RN 796598-90-8 CAPLUS

CN Benzoic acid, 3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)




RN 796598-97-5 CAPLUS

CN Benzoic acid, 4-chloro-3-[4-[(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl- (CA INDEX NAME)




RN 796599-05-8 CAPLUS

CN Benzoic acid, 3-[4-[(4-(3,4-dichlorophenoxy)-1-piperidinyl)methyl]-1-piperidinyl]-4-methoxy- (CA INDEX NAME)




RN 796599-12-7 CAPLUS

CN Benzoic acid, 3-[4-[(4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl)methyl]-1-piperidinyl- (CA INDEX NAME)




RN 796599-19-4 CAPLUS

CN Benzoic acid, 2-chloro-5-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796599-26-3 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 796599-33-2 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-2-methyl-1-piperidinyl]- (CA INDEX NAME)



RN 796599-40-1 CAPLUS

CN Benzoic acid, 3-[4-[[4-[(3,4-dichlorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2008:171091 CAPLUS Full-text  
 DOCUMENT NUMBER: 148:369281  
 TITLE: Overcoming Undesirable hERG Potency of Chemokine Receptor Antagonists Using Baseline Lipophilicity Relationships  
 AUTHOR(S): Shamovsky, Igor; Connolly, Stephen; David, Laurent; Ivanova, Svetlana; Norden, Bo; Springthorpe, Brian; Urbahns, Klaus  
 CORPORATE SOURCE: Department of Medicinal Chemistry, AstraZeneca R & D Lund, Lund, S-22187, Swed.  
 SOURCE: Journal of Medicinal Chemistry (2008), 51(5), 1162-1178  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB The inhibition of the hERG channel by noncardiovascular drugs is a side effect that severely impedes the development of new medications. To increase hERG selectivity of preclin. compds., the authors recommend the study of nondesolvation related interactions with the intended target and hERG using a baseline lipophilicity relationship approach. While this approach is conventionally used in studies of potency, the authors demonstrate here that it can help in selectivity issues. Studies of hERG selectivity in four inhouse classes of chemokine receptor (CCR) antagonists suggest that the selectivity is improved most effectively by structural alterations that increase the lipophilicity-adjusted primary potency,  $pIC50CCR - LogD$ . Fragment-based QSAR anal. is performed using the lipophilicity-adjusted hERG potency,  $pIC50hERG - LogD$ , to identify moieties that form nonhydrophobic interactions with the hERG channel. These moieties, which erode hERG selectivity, can then be avoided. A novel two-dimensional fragment-based QSAR anal. helps visualizing the lipophilicity-adjusted hERG and CCR potencies within chemical series.

IT 1013653-73-0D, derivs.

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (overcoming undesirable hERG potency of chemokine receptor antagonists using baseline lipophilicity relationships)

RN 1013653-73-0 CAPLUS

CN Benzoic acid, 2-[4-[(4-phenoxy-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)





REFERENCE COUNT: 110 THERE ARE 110 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:292021 CAPLUS Full-text  
 DOCUMENT NUMBER: 140:303547

TITLE: Preparation of piperidine derivatives for use in the treatment of chemokine mediated disease states  
 INVENTOR(S): Luckhurst, Christopher; Perry, Matthew; Springthorpe, Brian  
 PATENT ASSIGNEE(S): AstraZeneca Ab, Swed.  
 SOURCE: PCT Int. Appl., 72 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029041	A1	20040408	WO 2003-SE1425	20030912
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497280	A1	20040408	CA 2003-2497280	20030912
AU 2003259004	A1	20040419	AU 2003-259004	20030912
AU 2003259004	B2	20070208		
EP 1546130	A1	20050629	EP 2003-798620	20030912
EP 1546130	B1	20070801		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014688	A	20050802	BR 2003-14688	20030912
CN 1684952	A	20051019	CN 2003-822502	20030912
JP 2006503066	T	20060126	JP 2004-539695	20030912
NZ 538527	A	20061027	NZ 2003-538527	20030912
EP 1816123	A1	20070808	EP 2007-10143	20030912
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK				
AT 368656	T	20070815	AT 2003-798620	20030912
ES 2289354	T3	20080201	ES 2003-798620	20030912
MX 2005PA03007	A	20050622	MX 2005-PA3007	20050317
ZA 2005002341	A	20050919	ZA 2005-2341	20050318
US 20060040984	A1	20060223	US 2005-528477	20050318
NO 2005001965	A	20050623	NO 2005-1965	20050422
PRIORITY APPLN. INFO.:			SE 2002-2838	A 20020924
			EP 2003-798620	A3 20030912
			WO 2003-SE1425	W 20030912

OTHER SOURCE(S): MARPAT 140:303547  
 GI




AB Title compds. I [X = CH<sub>2</sub>, CO, O, SOO-2, amino; Y = bond, alkylene, etc.; Z = carboxy, aminosulfonyl, etc.; R<sub>1-2</sub> = H, alkyl, aryl, heterocycl; R<sub>4</sub> = H, alkyl; R<sub>3</sub> = H, OH] are prepared For instance, 4-[[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl]piperidine (preparation given) is reacted with glyoxylic acid and benzeneboronic acid (EtOH, microwave, 100°, 5 min) to give II. II has pKi = 7.2 for the H1 receptor. I are useful for the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

IT 676517-94-5P, 2-[[4-[[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl]piperidin-1-yl]-2,4-dimethoxypyrimidin-5-yl]acetic acid  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (novel piperidine derivs. for use in treatment of chemokine mediated disease states)

RN 676517-94-5 CAPLUS

CN 5-Pyrimidineacetic acid, 4-[[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-2,6-dimethoxy- (CA INDEX NAME)



=> d his nofil

(FILE 'HOME' ENTERED AT 14:07:19 ON 17 DEC 2008)

FILE 'REGISTRY' ENTERED AT 14:12:40 ON 17 DEC 2008

L1 STR  
 L2 6 SEA SSS SAM L1  
 L3 149 SEA SSS FUL L1

FILE 'CAPLUS' ENTERED AT 14:21:56 ON 17 DEC 2008

L4 6 SEA SPE=ON ABB=ON PLU=ON L3

FILE 'REGISTRY' ENTERED AT 14:22:08 ON 17 DEC 2008

L5 STR  
 L6 0 SEA SUB=L3 SSS SAM L5  
 L7 0 SEA SUB=L3 SSS FUL L5  
 D QUE  
 L8 STR L5  
 L9 6 SEA SUB=L3 SSS SAM L8  
 L10 138 SEA SUB=L3 SSS FUL L8

FILE 'WPIX' ENTERED AT 14:29:08 ON 17 DEC 2008

L11 0 SEA SSS SAM L1 AND L8  
 L12 3 SEA SSS FUL L1 AND L8  
 L13 2 SEA SPE=ON ABB=ON PLU=ON L12/DCR

FILE 'BEILSTEIN' ENTERED AT 14:29:37 ON 17 DEC 2008

L14 0 SEA SSS SAM L1 AND L8  
 L15 0 SEA SSS FUL L1 AND L8

FILE 'CAPLUS' ENTERED AT 14:30:23 ON 17 DEC 2008

L16 4 SEA SPE=ON ABB=ON PLU=ON L10

FILE 'CAPLUS' ENTERED AT 14:30:46 ON 17 DEC 2008

D QUE L16

FILE 'WPIX' ENTERED AT 14:30:53 ON 17 DEC 2008

D QUE L13

FILE 'CAPLUS, WPIX' ENTERED AT 14:31:00 ON 17 DEC 2008

L17 4 DUP REM L16 L13 (2 DUPLICATES REMOVED)  
 ANSWERS '1-4' FROM FILE CAPLUS  
 D L17 IBIB ABS HITSTR TOT

=> d his

(FILE 'HOME' ENTERED AT 14:07:19 ON 17 DEC 2008)

FILE 'REGISTRY' ENTERED AT 14:12:40 ON 17 DEC 2008

L1 STR  
 L2 6 S L1  
 L3 149 S L1 FUL

FILE 'CAPLUS' ENTERED AT 14:21:56 ON 17 DEC 2008

L4 6 S L3

FILE 'REGISTRY' ENTERED AT 14:22:08 ON 17 DEC 2008

L5 STR  
 L6 0 S L5 SAM SUB=L3  
 L7 0 S L5 FUL SUB=L3  
 L8 STR L5  
 L9 6 S L8 SAM SUB=L3  
 L10 138 S L8 FULL SUB=L3

FILE 'WPIX' ENTERED AT 14:29:08 ON 17 DEC 2008  
 L11 0 S L1 AND L8  
 L12 3 S L1 AND L8 FUL  
 L13 2 S L12/DCR

FILE 'BEILSTEIN' ENTERED AT 14:29:37 ON 17 DEC 2008  
 L14 0 S L1 AND L8  
 L15 0 S L1 AND L8 FUL

FILE 'CAPLUS' ENTERED AT 14:30:23 ON 17 DEC 2008  
 L16 4 S L10

FILE 'CAPLUS' ENTERED AT 14:30:46 ON 17 DEC 2008

FILE 'WPIX' ENTERED AT 14:30:53 ON 17 DEC 2008

FILE 'CAPLUS, WPIX' ENTERED AT 14:31:00 ON 17 DEC 2008  
 L17 4 DUP REM L16 L13 (2 DUPLICATES REMOVED)

=> fil reg  
 FILE 'REGISTRY' ENTERED AT 14:31:40 ON 17 DEC 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 DEC 2008 HIGHEST RN 1085590-90-4  
 DICTIONARY FILE UPDATES: 16 DEC 2008 HIGHEST RN 1085590-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d his

(FILE 'HOME' ENTERED AT 14:07:19 ON 17 DEC 2008)

FILE 'REGISTRY' ENTERED AT 14:12:40 ON 17 DEC 2008  
 L1 STR  
 L2 6 S L1  
 L3 149 S L1 FUL

FILE 'CAPLUS' ENTERED AT 14:21:56 ON 17 DEC 2008  
 L4 6 S L3

FILE 'REGISTRY' ENTERED AT 14:22:08 ON 17 DEC 2008  
 L5 STR  
 L6 0 S L5 SAM SUB=L3

L7 0 S L5 FUL SUB=L3  
L8 STR L5  
L9 6 S L8 SAM SUB=L3  
L10 138 S L8 FULL SUB=L3

FILE 'WPIX' ENTERED AT 14:29:08 ON 17 DEC 2008  
L11 0 S L1 AND L8  
L12 3 S L1 AND L8 FUL  
L13 2 S L12/DCR

FILE 'BEILSTEIN' ENTERED AT 14:29:37 ON 17 DEC 2008  
L14 0 S L1 AND L8  
L15 0 S L1 AND L8 FUL

FILE 'CAPLUS' ENTERED AT 14:30:23 ON 17 DEC 2008  
L16 4 S L10

FILE 'CAPLUS' ENTERED AT 14:30:46 ON 17 DEC 2008

FILE 'WPIX' ENTERED AT 14:30:53 ON 17 DEC 2008

FILE 'CAPLUS, WPIX' ENTERED AT 14:31:00 ON 17 DEC 2008  
L17 4 DUP REM L16 L13 (2 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 14:31:40 ON 17 DEC 2008